Plasma extracellular vesicle‑packaged microRNAs as candidate diagnostic biomarkers for early‑stage breast cancer

Yan,Chen; Hu,Jintao; Yang,Yipeng; Hu,Hong; Zhou,Dongxian; Ma,Min; Xu,Nan

doi:10.3892/mmr.2019.10669

Plasma extracellular vesicle‑packaged microRNAs as candidate diagnostic biomarkers for early‑stage breast cancer

Authors:
- Chen Yan
- Jintao Hu
- Yipeng Yang
- Hong Hu
- Dongxian Zhou
- Min Ma
- Nan Xu
View Affiliations

Affiliations: Department of Breast Surgery, The Second Clinical Medical College (Shenzhen People's Hospital) of Jinan University, Shenzhen, Guangdong 518020, P.R. China, Department of Pathology, The Second Clinical Medical College (Shenzhen People's Hospital) of Jinan University, Shenzhen, Guangdong 518020, P.R. China, College of Traditional Chinese Medicine, Institute of Integrated Traditional Chinese and Western Medicine, Jinan University, Guangzhou, Guangdong 510632, P.R. China
Published online on: September 10, 2019 https://doi.org/10.3892/mmr.2019.10669
Pages: 3991-4002
Copyright: © Yan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Extracellular vesicle‑packaged microRNAs (miRNAs) are a class of circulating miRNAs located in the plasma that are packaged into extracellular vesicles. The present study examined the expression profiles of extracellular vesicles and tissue miRNAs with the aim of investigating the miRNA signatures in early‑stage breast cancer. The present study identified and compared the extracellular vesicle‑packaged miRNA expression signature and tissue miRNA expression signature from healthy individuals (n=10) and patients with early‑stage breast cancer (n=12). A total of five miRNAs, including miRNA‑375, miRNA‑24‑2‑5p, miRNA‑548b‑5p, miRNA‑655‑3P and miRNA‑376b‑5p, were synchronized in extracellular vesicles and tissues of the breast cancer group when compared with the healthy group. The highest area under the curve (AUC) for a single miRNA was achieved with miRNA‑548b‑5p [AUC=0.785; 95% confidence interval (CI)=0.585‑0.984; P=0.022]. The highest overall AUC was achieved by the combination of miRNA‑375, miRNA‑655‑3p, miRNA‑548b‑5p and miRNA‑24‑2‑5p (AUC=0.808; 95% CI=0.629‑0.986; P=0.013). The Kaplan‑Meier curves and log test analysis results of these five miRNAs, especially those for miRNA‑548b‑5p, were partly consistent with the hypothesis. Two miRNAs (miRNA‑548b‑5p and miRNA‑376b‑5p) were positively associated with patient survival, while two miRNAs (miRNA‑375 and miRNA‑24‑2‑5p) were negatively associated with patient survival. The present study provided a set of plasma extracellular vesicle‑packaged miRNA‑based biomarkers for the diagnosis of early‑stage breast cancer.

View Figures

View References

1	Harbeck N and Gnant M: Breast cancer. Lancet. 389:1134–1150. 2017. View Article : Google Scholar : PubMed/NCBI
2	Bertoli G, Cava C and Castiglioni I: MicroRNAs: New biomarkers for diagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer. Theranostics. 5:1122–1143. 2015. View Article : Google Scholar : PubMed/NCBI
3	Opstal-van Winden AW, Rodenburg W, Pennings JL, van Oostrom CT, Beijnen JH, Peeters PH, van Gils CH and de Vries A: A bead-based multiplexed immunoassay to evaluate breast cancer biomarkers for early detection in pre-diagnostic serum. Int J Mol Sci. 13:13587–13604. 2012. View Article : Google Scholar : PubMed/NCBI
4	Sinn P, Aulmann S, Wirtz R, Schott S, Marmé F, Varga Z, Lebeau A, Kreipe H and Schneeweiss A: Multigene assays for classification, prognosis, and prediction in breast cancer: A critical review on the background and clinical utility. Geburtshilfe Frauenheilkd. 73:932–940. 2013. View Article : Google Scholar : PubMed/NCBI
5	Herranz H and Cohen SM: MicroRNAs and gene regulatory networks: Managing the impact of noise in biological systems. Genes Dev. 24:1339–1344. 2010. View Article : Google Scholar : PubMed/NCBI
6	Ashby J, Flack K, Jimenez LA, Duan Y, Khatib AK, Somlo G, Wang SE, Cui X and Zhong W: Distribution profiling of circulating microRNAs in serum. Anal Chem. 86:9343–9349. 2014. View Article : Google Scholar : PubMed/NCBI
7	Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, Mitchell PS, Bennett CF, Pogosova-Agadjanyan EL, Stirewalt DL, et al: Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA. 108:5003–5008. 2011. View Article : Google Scholar : PubMed/NCBI
8	Desrochers LM, Antonyak MA and Cerione RA: Extracellular vesicles: Satellites of information transfer in cancer and stem cell biology. Dev Cell. 37:301–309. 2016. View Article : Google Scholar : PubMed/NCBI
9	Tomasetti M, Lee W, Santarelli L and Neuzil J: Exosome-derived microRNAs in cancer metabolism: Possible implications in cancer diagnostics and therapy. Exp Mol Med. 49:e2852017. View Article : Google Scholar : PubMed/NCBI
10	Graveel CR, Calderone HM, Westerhuis JJ, Winn ME and Sempere LF: Critical analysis of the potential for microRNA biomarkers in breast cancer management. Breast Cancer (Dove Med Press). 7:59–79. 2015.PubMed/NCBI
11	Hannafon BN, Trigoso YD, Calloway CL, Zhao YD, Lum DH, Welm AL, Zhao ZJ, Blick KE, Dooley WC and Ding WQ: Plasma exosome microRNAs are indicative of breast cancer. Breast Cancer Res. 18:902016. View Article : Google Scholar : PubMed/NCBI
12	Gao Y, Cai Q, Huang Y, Li S, Yang H, Sun L, Chen K and Wang Y: MicroRNA-21 as a potential diagnostic biomarker for breast cancer patients: A pooled analysis of individual studies. Oncotarget. 7:34498–34506. 2016.PubMed/NCBI
13	Shimomura A, Shiino S, Kawauchi J, Takizawa S, Sakamoto H, Matsuzaki J, Ono M, Takeshita F, Niida S, Shimizu C, et al: Novel combination of serum microRNA for detecting breast cancer in the early stage. Cancer Sci. 107:326–334. 2016. View Article : Google Scholar : PubMed/NCBI
14	Eichelser C, Stuckrath I, Muller V, Milde-Langosch K, Wikman H, Pantel K and Schwarzenbach H: Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients. Oncotarget. 5:9650–9663. 2014. View Article : Google Scholar : PubMed/NCBI
15	Xiao CL, Mai ZB, Lian XL, Zhong JY, Jin JJ, He QY and Zhang G: FANSe2: A robust and cost-efficient alignment tool for quantitative next-generation sequencing applications. PLoS One. 9:e942502014. View Article : Google Scholar : PubMed/NCBI
16	Mortazavi A, Williams BA, McCue K, Schaeffer L and Wold B: Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods. 5:621–628. 2008. View Article : Google Scholar : PubMed/NCBI
17	Bloom JS, Khan Z, Kruglyak L, Singh M and Caudy AA: Measuring differential gene expression by short read sequencing: Quantitative comparison to 2-channel gene expression microarrays. BMC Genomics. 10:2212009. View Article : Google Scholar : PubMed/NCBI
18	Xie C, Mao X, Huang J, Ding Y, Wu J, Dong S, Kong L, Gao G, Li CY and Wei L: KOBAS 2.0: A web server for annotation and identification of enriched pathways and diseases. Nucleic Acids Res. (39): (Web Server Issue). W316–W322. 2011. View Article : Google Scholar : PubMed/NCBI
19	Herrera-Perez Z, Gretz N and Dweep H: A comprehensive review on the genetic regulation of cisplatin-induced nephrotoxicity. Curr Genomics. 17:279–293. 2016. View Article : Google Scholar : PubMed/NCBI
20	Wong NW, Chen Y, Chen S and Wang X: OncomiR: An online resource for exploring pan-cancer microRNA dysregulation. Bioinformatics. 34:713–715. 2018. View Article : Google Scholar : PubMed/NCBI
21	Rajkumar AP, Qvist P, Lazarus R, Lescai F, Ju J, Nyegaard M, Mors O, Børglum AD, Li Q and Christensen JH: Experimental validation of methods for differential gene expression analysis and sample pooling in RNA-seq. BMC Genomics. 16:5482015. View Article : Google Scholar : PubMed/NCBI
22	Robinson MD, McCarthy DJ and Smyth GK: edgeR: A bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 26:139–140. 2010. View Article : Google Scholar : PubMed/NCBI
23	de Souza Rocha Simonini P, Breiling A, Gupta N, Malekpour M, Youns M, Omranipour R, Malekpour F, Volinia S, Croce CM, Najmabadi H, et al: Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor alpha in breast cancer cells. Cancer Res. 70:9175–9184. 2010. View Article : Google Scholar : PubMed/NCBI
24	Zou Q, Yi W, Huang J, Fu F, Chen G and Zhong D: MicroRNA-375 targets PAX6 and inhibits the viability, migration and invasion of human breast cancer MCF-7 cells. Exp Ther Med. 14:1198–1204. 2017. View Article : Google Scholar : PubMed/NCBI
25	Fu H, Fu L, Xie C, Zuo WS, Liu YS, Zheng MZ and Yu JM: miR-375 inhibits cancer stem cell phenotype and tamoxifen resistance by degrading HOXB3 in human ER-positive breast cancer. Oncol Rep. 37:1093–1099. 2017. View Article : Google Scholar : PubMed/NCBI
26	Schrauder MG, Strick R, Schulz-Wendtland R, Strissel PL, Kahmann L, Loehberg CR, Lux MP, Jud SM, Hartmann A, Hein A, et al: Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection. PLoS One. 7:e297702012. View Article : Google Scholar : PubMed/NCBI
27	Yamamoto Y, Yoshioka Y, Minoura K, Takahashi RU, Takeshita F, Taya T, Horii R, Fukuoka Y, Kato T, Kosaka N and Ochiya T: An integrative genomic analysis revealed the relevance of microRNA and gene expression for drug-resistance in human breast cancer cells. Mol Cancer. 10:1352011. View Article : Google Scholar : PubMed/NCBI
28	Srivastava N, Manvati S, Srivastava A, Pal R, Kalaiarasan P, Chattopadhyay S, Gochhait S, Dua R and Bamezai RN: miR-24-2 controls H2AFX expression regardless of gene copy number alteration and induces apoptosis by targeting antiapoptotic gene BCL-2: A potential for therapeutic intervention. Breast Cancer Res. 13:R392011. View Article : Google Scholar : PubMed/NCBI
29	Lee YM, Lee JY, Ho CC, Hong QS, Yu SL, Tzeng CR, Yang PC and Chen HW: miRNA-34b as a tumor suppressor in estrogen-dependent growth of breast cancer cells. Breast Cancer Res. 13:R1162011. View Article : Google Scholar : PubMed/NCBI
30	Ke H, Zhao L, Feng X, Xu H, Zou L, Yang Q, Su X, Peng L and Jiao B: NEAT1 is required for survival of breast cancer cells through fus and mir-548. Gene Regul Syst Bio. 10:11–17. 2016.PubMed/NCBI
31	Shi Y, Qiu M, Wu Y and Hai L: miR-548-3p functions as an anti-oncogenic regulator in breast cancer. Biomed Pharmacother. 75:111–116. 2015. View Article : Google Scholar : PubMed/NCBI
32	Lv ZD, Kong B, Liu XP, Jin LY, Dong Q, Li FN and Wang HB: miR-655 suppresses epithelial-to-mesenchymal transition by targeting Prrx1 in triple-negative breast cancer. J Cell Mol Med. 20:864–873. 2016. View Article : Google Scholar : PubMed/NCBI
33	Liang HQ, Wang RJ, Diao CF, Li JW, Su JL and Zhang S: The PTTG1-targeting miRNAs miR-329, miR-300, miR-381, and miR-655 inhibit pituitary tumor cell tumorigenesis and are involved in a p53/PTTG1 regulation feedback loop. Oncotarget. 6:29413–29427. 2015. View Article : Google Scholar : PubMed/NCBI
34	An N, Luo X, Zhang M and Yu R: MicroRNA-376b promotes breast cancer metastasis by targeting Hoxd10 directly. Exp Ther Med. 13:79–84. 2017. View Article : Google Scholar : PubMed/NCBI
35	Li LJ, Huang Q, Zhang N, Wang GB and Liu YH: miR-376b-5p regulates angiogenesis in cerebral ischemia. Mol Med Rep. 10:527–535. 2014. View Article : Google Scholar : PubMed/NCBI